Markets ▾
Subscribe

BAF NEWS

BAF NEWS

Business

Latest

November 2025 Australian home prices: momentum holds as affordability bites

November 2025 Australian home prices rose 1.0% month-on-month, reaching a median of A$888,941, with Perth leading gains amid tight supply. The article examines how November 2025 Australian home prices reflect persistent affordability pressures, regional dynamics, and the outlook for buyers and sellers into 2026.
  • No Comments
Nexperia urges China units November 2025: Open letter and China–EU push aim to steady chip supply
Nexperia urges China units November 2025 highlights the company's public appeal for its China entities to re-engage and restore supply chain flows after regulatory disruptions. The article details the timeline of halted shipments, governance disputes, and proposed structured negotiations aimed at stabilizing cross-border chip logistics and minimizing production risks for customers.
November 2025 Wang Fuk Court fire: how a scaffolding blaze became a citywide reckoning
The November 2025 Wang Fuk Court fire, a major incident in Tai Po, Hong Kong, began on exterior scaffolding and rapidly spread across seven towers, resulting in at least 75 deaths and renewed scrutiny of fire safety codes. The article details the timeline, rescue efforts, suspected causes, and ongoing investigations, highlighting the role of bamboo scaffolding and compliance failures.
HP 6,000 job cuts 2028: AI reshuffle meets cloud buildouts and chip bets
HP 6,000 job cuts 2028 highlights HP's plan to reduce its workforce by up to 6,000 roles by FY2028 as part of an AI-driven restructuring aimed at saving $1 billion. The article also covers major tech sector developments, including Amazon's $50B AWS investment, Meta's Google TPU deal, Dell's AI server guidance, and key consumer and security trends.
Wegovy 7.2 mg FDA filing: Faster review, bigger weight loss, and the next deadlines
The Wegovy 7.2 mg FDA filing marks Novo Nordisk's bid to introduce a higher once-weekly dose for adults with obesity, aiming for faster review under the FDA's accelerated pilot program. The application builds on STEP UP trial data, showing greater average weight loss, and could lead to a decision within 1–2 months if accepted.
Best Buy raises FY26 guidance after Q3 beat
Best Buy raises FY26 guidance following a strong Q3 performance, with comparable sales up 2.7% and revenue surpassing expectations. The company attributes this outlook upgrade to steady consumer demand, category momentum in computing and gaming, and effective tariff management, setting a positive tone for the holiday quarter.
Amycretin phase 2 results 2025: Novo Nordisk posts double-digit weight loss and HbA1c gains
The amycretin phase 2 results 2025 show that Novo Nordisk’s dual GLP-1 and amylin agonist achieved up to 14.5% weight loss and significant HbA1c reductions in adults with type 2 diabetes over 36 weeks. Both weekly injection and daily oral regimens were well tolerated, supporting advancement to phase 3 trials in 2026.

Trending in Business

Stay in the loop